



Published in final edited form as:

Pharmacol Res. 2024 April ; 202: 107109. doi:10.1016/j.phrs.2024.107109.

Corrigendum to “New therapies towards a better glycemic control in youths with type 1 diabetes” [*Pharmacol. Res.* 2023 Aug 3;195:106882]

Roque Cardona-Hernandez^a, Klemen Dôvc^b, Torben Biester^c, Laya Ekhlaspour^d, Maddalena Macedoni^e, Martin Tauschmann^f, Chiara Mamei^g

^aDivision of Pediatric Endocrinology. Hospital Sant Joan de Déu, Barcelona, Spain

^bFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, Ljubljana, Slovenia

^cAUF DER BULT, Diabetes Center for Children and Adolescents, Hannover, Germany

^dDepartment of Pediatrics, Division of Endocrinology. University of California, San Francisco, CA, United States

^eDepartment of Pediatrics, V. Buzzi Children’s Hospital, Milan, Italy

^fDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria

^gDepartment of Pediatrics, V. Buzzi Children’s Hospital, Milan, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

chiara.mamei@unimi.it (C. Mamei).

The authors regret that the ‘Conflict of Interest’ section was not included in the original published article. The information is as follows:

Conflict of Interest

RCH reports speaker honoraria from Abbott Diabetes Care, Eli Lilly, Novo-Nordisk, Sanofi-Aventis and Medtronic and advisory board fees from Eli-Lilly, Novo-Nordisk and Abbott Diabetes Care.

K.D. served on advisory boards of Novo Nordisk, Pfizer and Sanofi. K. D. received honoraria for participation in the speaker’s bureau of Abbott, Eli Lilly, Medtronic, Novo-Nordisk, and Pfizer.

TBI declares speakers’ honoraria from Sanofi, Synlab, Ypsomed, Advisory board participation in Astra Zeneca, Medtronic, Senseonics. He is member of EXPAMED panel of EMA.

LE is funded by NIH 1K23DK121942. She has received consulting fees from Tandem Diabetes Care, and Ypsomed, Speaker fee from Insulet, and research support from Medtronic, Mannkind and JDRF. Her institution has received funding for research grants from Medtronic, Dexcom, Tandem, Insulet, and Beta Bionics.

MT reports having received speaker honoraria from Eli Lilly, Novo Nordisk and Medtronic, and advisory board fees from Abbott Diabetes Care.

CM and MM declared no conflict of interest.

The authors would like to apologise for any inconvenience caused.